Cataracts are the leading cause of blindness in adults older than age 50 worldwide.The global prevalence of cataracts has ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

The Food and Drug Administration (FDA) has approved Iluvien® (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious ...

Operator Good morning, and welcome to Ocugen's fourth quarter and full-year 2024 financial results and business update.

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) ...

Q4 2024 Earnings Call Transcript March 5, 2025 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.05 EPS, expectations were $-0.05. Operator: Good morning, and welcome to ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and generally well-tolerated treatment for DME with retreatment every 6 months ...

Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical ...

endophthalmitis or choroidal neovascularization and no adverse events of special interest; considerably slower lesion growth from baseline in treated eyes versus untreated fellow eyes at 6-month ...

There was one case each of nonserious intraocular inflammation and culture-positive endophthalmitis. There were no cases of ischemic neuropathy or serious intraocular inflammation, but the rate of ...

ENCELTO implantation has been associated with severe vision loss, infectious endophthalmitis, retinal tears and/or detachment, vitreous hemorrhage, implant extrusion, cataract formation ...

Unlike currently available treatments for GA, there were no cases of ischemic optic neuropathy, vasculitis, intraocular inflammation, endophthalmitis or choroidal neovascularization, and no ...